Abstract: The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions.

Abstract: This invention relates to a process for chemically treating a carbon-containing feedstock (e.g., a polymer-based feedstock), comprising contacting (e.g., by a hydrocracking reaction) the carbon-containing feedstock and a hydrogen stream in the presence of at least one hydrocracking catalyst to produce an alkane-containing product stream. The hydrocracking catalyst comprises at least one transition metal or transition metal sulfide supported on an oxide-containing support. This invention also relates to an alkane-containing mixture obtained by the process described herein and a system/apparatus for carrying out the process described herein.

Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

Abstract: An improved debris catcher and choke system for receiving a pressurized fluid stream from wellbore operations where a controller can selectively place a plurality of debris catchers in debris catching or flushing modes, and the cleaned fluids from one of the debris catchers can be used to flush one of the other debris catchers. One or more embodiments relate to systems and methods for utilizing debris catchers and choke valves.

Abstract: A heterogeneous catalyst composition including a metal and boron catalyst with boron dispersed in a molten matrix, where the molten matrix includes a eutectic mixture of alkali metal or alkaline earth metal salts or hydroxides. A process for preparing a heterogeneous catalyst composition, including combining a mixture of alkali metal or alkaline earth metal salts or hydroxides to form a matrix including a eutectic mixture, adding, to the matrix, a boron precursor and at least one metal catalyst precursor to form a catalyst precursor mixture, and heating the catalyst precursor mixture to a temperature of from 390° C. to 750° C. to form the heterogeneous catalyst composition. A process for catalytic oxidative dehydrogenation of hydrocarbons whereby a hydrocarbon-containing feedstock contacts the heterogeneous catalyst composition to generate olefinic compounds.

Abstract: A document management system can include an artificial intelligence-based document manager that can perform one or more predictive operations based on characteristics of a user, a document, a user account, or historical document activity. For instance, the document management system can apply a machine-learning model to determine how long an expiring agreement document is likely to take to renegotiate and can prompt a user to begin the renegotiation process in advance. The document management system can detect a change to language in a particular clause type and can prompt a user to update other documents that include the clause type to include the change. The document management system can determine a type of a document being worked on and can identify one or more actions that a corresponding user may want to take using a machine-learning model trained on similar documents and similar users.

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: The present system and method is directed to a process to facilitate trusted sources of information in an enterprise. The present system and method positions data governance to move away from the element level and focus on the data asset (i.e. repository, interface, subject) level. When data persons are having any issue with their data asset, whether it is a conflicting data asset, interface issues, competing data asset, new data asset build, data subject issue, or the like, a certifier may operate to assess the asset based on our well defined metrics, determine the health through the data asset scoring process, recommend asset services, and provide those services to the data owner who is ultimately responsible for implementing them to improve the data and the data processes.

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: Systems and methods are disclosed herein for generating and modifying a workflow comprising a series of webpages based on an online document. A document management system accesses an online document selected by a user and classifies each field of the online document into one of a set of categories. For each category, the system generates a form webpage comprising questions corresponding to each field classified as the category and combines the generated webpages to create a workflow. The system may modify the workflow by generating and adding one or more additional form webpages based on one or more answers provided by an entity completing the webform page. In response to the entity completing the modified generated workflow, the system generates a completed document based on the online document and the answers provided by the entity.

Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Abstract: A heterogeneous catalyst composition may include a metal catalyst supported on a porous mixed metal oxide support. A process for catalytic oxidative dehydrogenation of hydrocarbons may include contacting, in a reactor system, a hydrocarbon-containing feedstock with the heterogeneous catalyst composition to generate olefinic compounds. A process for preparing a heterogeneous catalyst composition may include combining a porous mixed metal oxide support with at least one metal catalyst precursor to form a catalyst precursor mixture, wherein the at least one metal catalyst precursor comprises at least one metal compound selected from the group consisting of transition metal compounds, rare-earth metal compounds, or a mixture thereof, and heating the catalyst precursor mixture to a temperature of about 390° C. to about 750° C. to form a heterogeneous catalyst composition.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for evaluating interactions with a user interface are disclosed. In one aspect, a method includes identifying a set of mutation events specifying changes to the structure of a user interface that occurred during the user session, and generating user interface states specifying different structures of the user interface throughout the given user session. Based at least in part on the user interface states, playback data that present visual changes of the user interface corresponding to the set of mutation events that occurred during the user session are generated. Session activity data describing user interactions that occurred during the user session are also generated. At least a portion of the playback data and the session activity data are output to a requesting device.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: According to some embodiments, an enterprise proprietary data store contains a set of electronic data records, each electronic data record having with proprietary data and an associated governance structure. A compliance computer platform may receive the proprietary data and associated governance structure from the enterprise proprietary data store and define enterprise-wide decision accountabilities for the proprietary data based on the governance structure. The compliance computer platform may also define privacy objectives for the proprietary data based on the governance structure along with specific machine-level controls to test and confirm compliance with the governance structure.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A process for the cracking of a carbon-containing feedstock to produce olefins, the process includes contacting, in a reactor system, the carbon-containing feedstock with a molten salt matrix consisting of a eutectic mixture of alkali metal carbonates, alkaline earth metal carbonates, or a mixture of any two or more thereof, to generate an olefin-containing product stream; and collecting an olefin from the olefin-containing product stream; wherein: the process is conducted in the absence of oxygen, and in the absence of a catalyst comprising a transition metal, a transition metal oxide, a rare-earth metal, a rare earth metal oxide, or a combination of any two or more thereof.

Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.